Maxim Group analyst Jason McCarthy maintained a Buy rating on BioLife Solutions (BLFS – Research Report) yesterday and set a price target of $34.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason McCarthy has given his Buy rating due to a combination of factors including BioLife Solutions’ strong financial performance and strategic acquisitions. The company reported a significant year-over-year increase in revenue for the first quarter of 2025, alongside a healthy cash reserve, which positions it well to support ongoing operations and potential future growth.
Moreover, BioLife Solutions’ acquisition of PanTHERA Cryosolutions is expected to enhance its core offerings in the cell and gene therapy market. The integration of PanTHERA’s innovative Ice Recrystallization Inhibitor technology into BioLife’s cryopreservation products is anticipated to improve product efficacy and reduce costs associated with cold chain logistics. This strategic move, coupled with the company’s focus on expanding its product lines and increasing revenue per dose, underscores its potential for sustained growth and market leadership.
In another report released on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.
BLFS’s price has also changed slightly for the past six months – from $24.110 to $23.090, which is a -4.23% drop .